CGEM Stock — Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. (CGEM)

Updated October 16, 2026.

CGEM is a Stock. Total return is -56.8% over the past 5.8 years, 172.9 points behind SPY at 116.1%.

Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer, including bispecific T cell engagers in early trials and an oral lung cancer treatment in mid-stage development. The company does not currently have an established distribution program. The company appeals to investors with high risk tolerance who are interested in early-stage biotechnology development.

CGEM performance versus SPY

Price and return data through 2026-10-16.

Total return is -56.8% over the past 5.8 years, 172.9 points behind SPY at 116.1%. Over the past year its total return — price change plus distributions reinvested — is 47.9%. Its deepest 1-year drawdown was 43.7%.

CGEM key facts

Asset type

Stock

Asset class

Equity

Inception date

01/08/2021

Distribution frequency

None

Last close

$12.93 (as of 2026-10-16)

Market cap

$794,652,535

Average volume

1123252.0

Beta

0.02

Payout ratio

0.0%

Forward P/E

6.7385

EPS

$-3.11

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CGEM risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 43.7%.

Who may consider CGEM — and who may not

It is a weaker fit for investors who need monthly cash flow (CGEM does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CGEM

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions